Overview
- Editors:
-
-
Vladimir Muzykantov
-
School of Medicine, University of Pennsylvania, Philadelphia, USA
-
Vladimir Torchilin
-
School of Pharmacy, Northeastern University, Boston, USA
Access this book
Other ways to access
Table of contents (25 chapters)
-
Front Matter
Pages i-xvii
-
General Principles of Drug Targeting
-
-
-
-
Cardiovascular Targeting
-
-
-
-
- Karlheinz Peter, Christoph Bode
Pages 85-106
-
- Lucy A. Carver, Jan E. Schnitzer
Pages 107-128
-
-
- Jonathan R. Lindner, Alexander L. Klibanov, Klaus Ley
Pages 149-172
-
- Paul N. Reynolds, Sergei M. Danilov
Pages 173-190
-
Tumor Targeting
-
Front Matter
Pages 191-191
-
-
-
- Sophia Ran, Michael Rosenblum, Philip E. Thorpe
Pages 229-248
-
- Alan L. Epstein, Leslie A. Khawli, Peisheng Hu
Pages 249-274
-
- Susanna M. Rybak, Michaela Arndt, Juergen Krauss, Dianne L. Newton, Bang K. Vu, Zhongyu Zhu
Pages 275-290
-
- Victor S. Goldmacher, Walter A. Blättler, John M. Lambert, Ravi V. J. Chari
Pages 291-309
-
Targeting to the Brain
-
Front Matter
Pages 311-311
About this book
Drugs usually have no natural affinity for the cells, tissues and organs where therapeutic effects are needed, which frequently results in low efficiency and unwanted side effects. This concern is even more profound when using highly potent and cytotoxic anticancer drugs or specific agents, such as enzymes and genetic materials, since their effective and safe action requires precise cellular or even sub-cellular addressing in the target organ. To meet safety, efficiency and specificity requirements, drugs somehow must be targeted to the sites of their expected therapeutic action. The idea of the "magic bullet," or drug targeting, proposed by Erlich a century ago, generates great and continuously growing interest in biomedical, industrial and financial circles. This book is focused on the strategies designed to target therapeutic or diagnostic agents to the disease sites. In an attempt to include in this volume the set of chapters reflecting both traditional and emerging areas of drug targeting, we have contacted many leading scientists in the field asking for their contributions. Their responses were most favorable and encouraging. As a result, we have succeeded in assembling a series of outstanding contributions reflecting practically all the key areas of drug targeting. The final structure of this book is as follows.
Editors and Affiliations
-
School of Medicine, University of Pennsylvania, Philadelphia, USA
Vladimir Muzykantov
-
School of Pharmacy, Northeastern University, Boston, USA
Vladimir Torchilin